Authors
Latest:
CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPCAjay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.
Latest:
New Strategy Boosts Microenvironment to Promote Antitumor Immunity in GI MetastasesDespite the promise of immunotherapy for treating patients with advanced cancers, the success of using such therapies for progressive gastrointestinal malignancies such as colorectal liver metastases (CRLM) has been limited so far.
Latest:
Dr. Alva on the Shift Toward Combination Therapy in mRCCAjjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Latest:
Staying Afloat When the Floodgates OpenIt is quite easy to be drowned in the rising floodwaters of hematology and medical oncology, especially when you start training.
Latest:
Dr. Patnaik on Challenges With Sequencing Therapies in mCRPCAkash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Targeted Therapies in Advanced Renal Cell Cancer: A Critical ReviewIn order to help community oncologists optimize patient outcomes, this review summarizes clinical issues associated with specific therapies and the background pivotal data.
Latest:
Dr. Shimomura Discusses the HERB TEA Study in HER2+ Breast CancerAkihiko Shimomura, MD, PhD, Department of Breast and Medical Oncology, Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, discusses the HERB TEA trial (JCOG1607) in patients with HER2-positive breast cancer.
Latest:
International Hematology/Oncology Elective: A Unique Learning ExperienceAlthough minor institution-specific variations exist, traditional fellowship programs in the United States are able to provide training in the sophisticated Western style of practice.
Latest:
Dr. Puri on Challenges With Treating Older Patients With Pancreatic CancerAkshjot Puri, MD, discusses challenges facing older patients with pancreatic cancer.
Latest:
Dr. Benson on the Complexity of Up-front Treatment in HCCAl B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.
Latest:
Dr. Algazi on Benefit of Continuous Dabrafenib/Trametinib Dosing in BRAF+ MelanomaAlain Algazi, MD, discusses the benefit of continuous dosing with dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF mutation–positive advanced melanoma.
Latest:
Dr. Mita on Emergence of Checkpoint Inhibitors SCLCAlain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.
Latest:
Practice in South Texas Offers Vertically Integrated Cancer CareProviding comprehensive, compassionate, cost-effective care has been the guiding principle of Urology San Antonio. The practice manages over 200,000 visits and establishes relationships with more than 22,000 new patients each year.
Latest:
Healthcare IT Still Seeks a Security BlanketAugust has traditionally been a sleepy month for government regulatory agencies, but this year, Washington's usual summer torpor was interrupted by a rush of new initiatives, as more than three-quarters of a trillion dollars from the American Recovery and Reinvestment Act surged into a mind- boggling range of projects.
Latest:
nmCRPC: Clinical Trial Data on AR InhibitorsShared insight on the SPARTAN, PROSPER, and ARAMIS studies with androgen receptor (AR) inhibitors in non-metastatic castration-resistant prostate cancer.
Latest:
Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid LeukemiaOne promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.
Latest:
Dr. Venook on the Unmet Need Addressed by The GALAXY Trial Examining ctDNA in CRCAlan P. Venook, MD, discusses the unmet need addressed by the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.
Latest:
A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS TrialTreating MRI-identified prostate lesions to definitive doses using an SIHB is possible without significantly increased dose or acute toxicity to critical structures
Latest:
Dr. Sandler on Immunotherapies to Treat Lung CancerDr. Alan Sandler from the Oregon Health & Science University Discusses Immunotherapies for Lung Cancer
Latest:
Expert Discusses Mutations in MelanomaAlan Shain, PhD, postdoctoral scholar, UCSF School of Medicine, discusses the role of genetics in melanoma.
Latest:
Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCLAlan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.
Latest:
3-D Printing Technology Enhances Limb Preservation in Cancer OperationsLimb preservation is now the procedure of choice for the treatment of patients with bone cancer.
